[{"NetIncomeLoss_1_Q3_USD":-49983000.0,"GainLossOnSaleOfPropertyPlantEquipment_3_Q3_USD":7470000.0,"GainLossOnSaleOfPropertyPlantEquipment_1_Q3_USD":7463000.0,"PaymentsForRestructuring_3_Q3_USD":2603000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":8420000.0,"ProceedsFromDivestitureOfBusinesses_3_Q3_USD":8100000.0,"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q3_USD":5535000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q3_USD":841000.0,"AssetsCurrent_0_Q3_USD":133416000.0,"RestructuringCharges_3_Q3_USD":2676000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":41499610.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q3_USD":335000.0,"ResearchAndDevelopmentInProcess_3_Q3_USD":44812000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q3_USD":2497000.0,"CommonStockSharesIssued_0_Q3_shares":10677285.0,"Assets_0_Q3_USD":139870000.0,"ShareBasedCompensation_3_Q3_USD":5151000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":5046000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.001,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":10670000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.001,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q3_USD":677000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":2769000.0,"CommonStockSharesAuthorized_0_Q3_shares":150000000.0,"CommitmentsAndContingencies_0_Q3_USD":null,"OperatingIncomeLoss_3_Q3_USD":-70743000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":9850530.0,"GeneralAndAdministrativeExpense_1_Q3_USD":5598000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":19630000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":5003000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q3_USD":6356000.0,"ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_3_Q3_USD":98907000.0,"CommonStockValue_0_Q3_USD":11000.0,"OtherNonoperatingIncome_3_Q3_USD":239000.0,"OtherNonoperatingIncome_1_Q3_USD":239000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":110060000.0,"CostsAndExpenses_3_Q3_USD":78614000.0,"CostsAndExpenses_1_Q3_USD":57511000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_3_Q3_USD":-63470000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q3_USD":-49983000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-63470000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-49983000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":-2544000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":129420000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":3691000.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":165177000.0,"Liabilities_0_Q3_USD":23812000.0,"OperatingLeaseLiability_0_Q3_USD":5679000.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"DepreciationAndAmortization_3_Q3_USD":703000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":12074000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":8392741.0,"OperatingIncomeLoss_1_Q3_USD":-57199000.0,"RestructuringReserve_0_Q3_USD":73000.0,"InvestmentIncomeInterest_3_Q3_USD":73000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q3_USD":2424000.0,"LiabilitiesCurrent_0_Q3_USD":20121000.0,"AccountsPayableCurrent_0_Q3_USD":639000.0,"NonoperatingIncomeExpense_3_Q3_USD":7273000.0,"NonoperatingIncomeExpense_1_Q3_USD":7216000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":130675000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_3_Q3_USD":48000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":3996000.0,"ProceedsFromStockOptionsExercised_3_Q3_USD":435000.0,"SeveranceCosts1_3_Q3_USD":2700000.0,"SeveranceCosts1_1_Q3_USD":900000.0,"DefinedContributionPlanEmployerDiscretionaryContributionAmount_3_Q3_USD":0.0,"DefinedContributionPlanEmployerDiscretionaryContributionAmount_1_Q3_USD":0.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":1843000.0,"SubleaseIncome_3_Q3_USD":239000.0,"IncreaseDecreaseInOtherOperatingAssets_3_Q3_USD":-427000.0,"LesseeOperatingLeaseDiscountRate_0_Q3_pure":0.095,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q3_USD":13000.0,"OperatingLeasePayments_3_Q3_USD":2137000.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"DividendsCommonStock_1_Q3_USD":11450000.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":153000.0,"NetIncomeLoss_3_Q3_USD":-63470000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-26484000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":3512000.0,"ProceedsFromSaleOfPropertyPlantAndEquipment_3_Q3_USD":320000.0,"RestrictedCashNoncurrent_0_Q3_USD":1255000.0,"InvestmentIncomeInterest_1_Q3_USD":23000.0,"PreferredStockValue_0_Q3_USD":null,"DeferredIncomeTaxExpenseBenefit_26_Q3_USD":0.0,"OperatingLeaseCost_3_Q3_USD":1366000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":139870000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":1098000.0,"PreferredStockSharesAuthorized_0_Q3_shares":9000000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":5151000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":3512000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":1988000.0,"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3_Q3_USD":-1596000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q3_USD":594000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-7.56,"ProfitLoss_3_Q3_USD":-63470000.0,"StockholdersEquity_0_Q3_USD":-22174000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_3_Q3_USD":7871000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_1_Q3_USD":312000.0,"VariableLeaseCost_3_Q3_USD":693000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-187362000.0,"CurrentIncomeTaxExpenseBenefit_26_Q3_USD":0.0,"LeaseCost_3_Q3_USD":1820000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":91996000.0,"IncreaseDecreaseInAccountsReceivable_3_Q3_USD":-2000000.0,"CommonStockSharesOutstanding_0_Q3_shares":10677285.0,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-5.07,"IncreaseDecreaseInContractWithCustomerLiability_3_Q3_USD":-1315000.0,"Ticker":"COGT","CIK":"1622229","name":"COGENT BIOSCIENCES, INC.","OfficialName":"Cogent Biosciences Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"369716293.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201109"}]